DGX · Quest Diagnostics Incorporated
$198.022026-05-17Sector: Healthcare; Industry: Medical - Diagnostics & Research; Sub-Industry: Health Care Services
Intrinsic Value Range Comparison · Mulya.ai
Base · active
$65
-67.1% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($66 · $131) Analysts Range ($200 · $235) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2021.Q4 | $10.8B | — | 22.1% | 22.3% | $1.9B | $516MM | $2.4B | 5.3% | — | 19.0% | $9.7B | $17.81 | — |
| 2022.Q4 | $9.9B | -8.4% | 14.4% | 20.6% | $1.1B | $8MM | $1.1B | 6.7% | — | 11.7% | $9.7B | $8.45 | — |
| 2023.Q4 | $9.3B | -6.4% | 13.6% | 21.5% | $991MM | −$725MM | $266MM | 6.6% | — | 9.8% | $10.5B | $7.63 | — |
| 2024.Q4 | $9.9B | 6.7% | 13.6% | 22.9% | $1.0B | −$2.3B | −$1.3B | 7.2% | — | 9.0% | $12.6B | $7.78 | — |
| 2025.Q4 | $11.0B | 11.8% | 14.1% | 23.1% | $1.2B | −$139MM | $1.1B | 7.0% | — | 9.3% | $13.1B | $8.86 | 14.2 |
| italics below = DCF projection · 10yr Rev CAGR: 5.3% |
| 2026.Q4 | $11.8B | +6.6% | 14.6% | 22.8% | $1.3B | −$1.4B | −$43MM | 7.2% | −$40MM | 9.6% | $14.5B | $11.83 | 16.7 |
| 2027.Q4 | $12.5B | +6.3% | 14.6% | 22.5% | $1.4B | −$1.2B | $245MM | 7.4% | $213MM | 9.4% | $15.7B | $12.63 | 15.7 |
| 2028.Q4 | $13.3B | +6.0% | 14.6% | 22.2% | $1.5B | −$1.0B | $483MM | 7.5% | $391MM | 9.3% | $16.7B | $13.45 | 14.7 |
| 2029.Q4 | $14.0B | +5.8% | 14.6% | 21.9% | $1.6B | −$1.2B | $425MM | 7.7% | $319MM | 9.3% | $17.9B | $14.28 | 13.9 |
| 2030.Q4 | $14.8B | +5.5% | 14.6% | 21.5% | $1.7B | −$1.1B | $550MM | 7.8% | $383MM | 9.2% | $19.0B | $15.12 | 13.1 |
|
| Term. Yr+ | $19.3B | 4.1% | 11.8% | 20.0% | $1.8B | −$867MM | $952MM | 8.6% | $9.9B | 8.6% | — | — | — |
Active scenario IV: $65 (-67.1% vs market)